<DOC>
	<DOCNO>NCT01505647</DOCNO>
	<brief_summary>This study determine whether ZOSTAVAX™ make alternative manufacturing process [ ZOSTAVAX™ ( AMP ) ] well tolerate immunogenic , comparable immune response ZOSTAVAX™ .</brief_summary>
	<brief_title>Safety Immunogenicity Zoster Vaccine ( ZOSTAVAX™ ) Made With Alternative Manufacturing Process ( AMP ) ( V211-042 AM1 )</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>No fever day vaccination History varicella residence VZVendemic area ≥30 year Females reproductive potential must negative pregnancy test must agree use acceptable method birth control History hypersensitivity reaction vaccine component Prior receipt varicella zoster vaccine Prior history herpes zoster Have recently another vaccination Pregnant breastfeeding Use immunosuppressive therapy Known suspect immune dysfunction Concomitant antiviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>